{"id":31686,"date":"2025-10-02T09:20:38","date_gmt":"2025-10-02T13:20:38","guid":{"rendered":"https:\/\/www.cosprc.ca\/?p=31686"},"modified":"2025-10-02T09:35:33","modified_gmt":"2025-10-02T13:35:33","slug":"guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2","status":"publish","type":"post","link":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/","title":{"rendered":"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0"},"content":{"rendered":"\n<figure class=\"wp-block-image size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"962\" height=\"257\" src=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019.png\" alt=\"\" class=\"wp-image-31687\" srcset=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019.png 962w, https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019-300x80.png 300w, https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019-768x205.png 768w\" sizes=\"auto, (max-width: 962px) 100vw, 962px\" \/><\/figure>\n\n\n\n<p><em>Cr\u00e9\u00e9 le 16 juillet 2021<\/em><br><em>R\u00e9vis\u00e9 le 19 septembre 2025<\/em><\/p>\n\n\n\n<p>Visudyne est un agent th\u00e9rapeutique essentiel pour le traitement de certaines maladies de la r\u00e9tine et choro\u00efdiennes mena\u00e7ant la vision, y compris les tumeurs choro\u00efdiennes, la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge (DMLA) n\u00e9ovasculaire\u00a0r\u00e9sistante aux anti-VEGF et la choro\u00efdite s\u00e9reuse centrale (CCS). Une p\u00e9nurie mondiale active de Visudyne est en cours, et le prochain approvisionnement au Canada n\u2019est pas pr\u00e9vu avant la fin du mois de juin 2026 (voir\u00a0: <a href=\"https:\/\/www.penuriesdemedicamentscanada.ca\/?\">penuriesdemedicamentscanada.ca<\/a>).\u00a0<\/p>\n\n\n\n<p>La Soci\u00e9t\u00e9 canadienne de la r\u00e9tine (SCR) et la Soci\u00e9t\u00e9 canadienne d\u2019ophtalmologie (SCO) collaborent avec l\u2019Unit\u00e9 des p\u00e9nuries de m\u00e9dicaments de Sant\u00e9 Canada sur cette question. En outre, la SCR et la SCO proposent les strat\u00e9gies d\u2019att\u00e9nuation suivantes et sugg\u00e8rent que les stocks restants de Visudyne soient prioris\u00e9s de la fa\u00e7on suivante\u00a0:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Priorit\u00e9\u00a01\u00a0: Pour l\u2019ensemble du traitement et de la prise en charge des tumeurs oculaires mena\u00e7ant la vision<\/li>\n\n\n\n<li>Priorit\u00e9 2\u00a0: Pour le traitement de la CSC non r\u00e9solutive<\/li>\n\n\n\n<li>Priorit\u00e9 3\u00a0: Pour le traitement de la DMLA n\u00e9ovasculaire r\u00e9sistante aux anti-VEGF<\/li>\n<\/ul>\n\n\n\n<p>La SCR et la SCO fournissent ces renseignements \u00e0 titre d\u2019orientation et encouragent tous les ophtalmologistes traitants \u00e0 collaborer avec leurs groupes locaux et r\u00e9gionaux de sp\u00e9cialistes en oncologie et de la r\u00e9tine afin de garantir une r\u00e9partition rigoureuse de cet agent aupr\u00e8s des patients les plus gravement atteints.<\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cr\u00e9\u00e9 le 16 juillet 2021R\u00e9vis\u00e9 le 19 septembre 2025 Visudyne est un agent th\u00e9rapeutique essentiel pour le traitement de certaines maladies de la r\u00e9tine et choro\u00efdiennes mena\u00e7ant la vision, y compris les tumeurs choro\u00efdiennes, la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge (DMLA) n\u00e9ovasculaire\u00a0r\u00e9sistante aux anti-VEGF et la choro\u00efdite s\u00e9reuse centrale (CCS). Une p\u00e9nurie mondiale active de [&hellip;]<\/p>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[304,305,306],"post_tag":[],"content_type":[326],"class_list":["post-31686","post","type-post","status-publish","format-standard","hentry","category-pour-les-etudiants-en-medecine","category-pour-les-ophtalmologistes","category-pour-les-residents-et-les-boursiers","content_type-enonce-de-principes-et-lignes-directrices"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0 - Practice Resource Centre<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0 - Practice Resource Centre\" \/>\n<meta property=\"og:description\" content=\"Cr\u00e9\u00e9 le 16 juillet 2021R\u00e9vis\u00e9 le 19 septembre 2025 Visudyne est un agent th\u00e9rapeutique essentiel pour le traitement de certaines maladies de la r\u00e9tine et choro\u00efdiennes mena\u00e7ant la vision, y compris les tumeurs choro\u00efdiennes, la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge (DMLA) n\u00e9ovasculaire\u00a0r\u00e9sistante aux anti-VEGF et la choro\u00efdite s\u00e9reuse centrale (CCS). Une p\u00e9nurie mondiale active de [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Practice Resource Centre\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-02T13:20:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-02T13:35:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019.png\" \/>\n\t<meta property=\"og:image:width\" content=\"962\" \/>\n\t<meta property=\"og:image:height\" content=\"257\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Admin Assistant\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Admin Assistant\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/\"},\"author\":{\"name\":\"Admin Assistant\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/9ab88c133cdbf69968d498a38588ee75\"},\"headline\":\"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0\",\"datePublished\":\"2025-10-02T13:20:38+00:00\",\"dateModified\":\"2025-10-02T13:35:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/\"},\"wordCount\":270,\"image\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Screenshot-2025-10-02-092019.png\",\"articleSection\":[\"Pour les \u00e9tudiants en m\u00e9decine\",\"Pour les ophtalmologistes\",\"Pour les r\u00e9sidents et les boursiers\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/\",\"name\":\"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0 - Practice Resource Centre\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Screenshot-2025-10-02-092019.png\",\"datePublished\":\"2025-10-02T13:20:38+00:00\",\"dateModified\":\"2025-10-02T13:35:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/9ab88c133cdbf69968d498a38588ee75\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Screenshot-2025-10-02-092019.png\",\"contentUrl\":\"https:\\\/\\\/www.cosprc.ca\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/Screenshot-2025-10-02-092019.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#website\",\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/\",\"name\":\"Practice Resource Centre\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.cosprc.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.cosprc.ca\\\/#\\\/schema\\\/person\\\/9ab88c133cdbf69968d498a38588ee75\",\"name\":\"Admin Assistant\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g\",\"caption\":\"Admin Assistant\"},\"url\":\"https:\\\/\\\/www.cosprc.ca\\\/fr\\\/author\\\/h4gznwtqqyl8bwjg\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0 - Practice Resource Centre","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/","og_locale":"fr_FR","og_type":"article","og_title":"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0 - Practice Resource Centre","og_description":"Cr\u00e9\u00e9 le 16 juillet 2021R\u00e9vis\u00e9 le 19 septembre 2025 Visudyne est un agent th\u00e9rapeutique essentiel pour le traitement de certaines maladies de la r\u00e9tine et choro\u00efdiennes mena\u00e7ant la vision, y compris les tumeurs choro\u00efdiennes, la d\u00e9g\u00e9n\u00e9rescence maculaire li\u00e9e \u00e0 l\u2019\u00e2ge (DMLA) n\u00e9ovasculaire\u00a0r\u00e9sistante aux anti-VEGF et la choro\u00efdite s\u00e9reuse centrale (CCS). Une p\u00e9nurie mondiale active de [&hellip;]","og_url":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/","og_site_name":"Practice Resource Centre","article_published_time":"2025-10-02T13:20:38+00:00","article_modified_time":"2025-10-02T13:35:33+00:00","og_image":[{"width":962,"height":257,"url":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019.png","type":"image\/png"}],"author":"Admin Assistant","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Admin Assistant","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/#article","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/"},"author":{"name":"Admin Assistant","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/9ab88c133cdbf69968d498a38588ee75"},"headline":"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0","datePublished":"2025-10-02T13:20:38+00:00","dateModified":"2025-10-02T13:35:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/"},"wordCount":270,"image":{"@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019.png","articleSection":["Pour les \u00e9tudiants en m\u00e9decine","Pour les ophtalmologistes","Pour les r\u00e9sidents et les boursiers"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/","url":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/","name":"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0 - Practice Resource Centre","isPartOf":{"@id":"https:\/\/www.cosprc.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/#primaryimage"},"image":{"@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019.png","datePublished":"2025-10-02T13:20:38+00:00","dateModified":"2025-10-02T13:35:33+00:00","author":{"@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/9ab88c133cdbf69968d498a38588ee75"},"breadcrumb":{"@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/#primaryimage","url":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019.png","contentUrl":"https:\/\/www.cosprc.ca\/wp-content\/uploads\/2025\/10\/Screenshot-2025-10-02-092019.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.cosprc.ca\/fr\/guidelines-for-supply-triage-during-visudyne-verteporfin-shortage-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.cosprc.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"Lignes directrices pour la r\u00e9partition prioritaire des stocks durant la p\u00e9nurie de Visudyne (vert\u00e9porfine)\u00a0"}]},{"@type":"WebSite","@id":"https:\/\/www.cosprc.ca\/#website","url":"https:\/\/www.cosprc.ca\/","name":"Practice Resource Centre","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.cosprc.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/www.cosprc.ca\/#\/schema\/person\/9ab88c133cdbf69968d498a38588ee75","name":"Admin Assistant","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1bb7ba3166135b524438491f96bc4d09514b58d4153f0c5fa19182fb727d6850?s=96&d=mm&r=g","caption":"Admin Assistant"},"url":"https:\/\/www.cosprc.ca\/fr\/author\/h4gznwtqqyl8bwjg\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-30 02:26:51","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/31686","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/comments?post=31686"}],"version-history":[{"count":3,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/31686\/revisions"}],"predecessor-version":[{"id":31699,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/posts\/31686\/revisions\/31699"}],"wp:attachment":[{"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/media?parent=31686"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/categories?post=31686"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/post_tag?post=31686"},{"taxonomy":"content_type","embeddable":true,"href":"https:\/\/www.cosprc.ca\/fr\/wp-json\/wp\/v2\/content_type?post=31686"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}